Sanofi and Regeneron’s Dupixent Approved for COPD, 'Smoker's Lungs,' in EU

Jul 3, 2024, 05:15 AM

Sanofi and its partner Regeneron have received European Union approval on Wednesday for the expanded use of their Dupixent injection to treat patients with chronic obstructive pulmonary disease (COPD). This marks the first-ever targeted therapy for COPD, also referred to as 'smoker's lungs,' approved in the EU. Notably, the EU's approval process for Dupixent was faster than that of the United States, highlighting a rare instance of expedited clearance. The approval is expected to create a new growth avenue for the blockbuster drug.